AbCellera explained

AbCellera Biologics Inc.
Type:Public
Traded As:NASDAQ:
Industry:Biotechnology
Location:Vancouver, British Columbia
Revenue:38 million (2023)
Net Income: US -$146 million (2023)
Num Employees:386 (2021)

AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology firm that researches and develops human antibodies. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office.[1] AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days."[2] Its platform for single-cell screening was initially developed at the University of British Columbia.[3]

History

AbCellera was founded in 2012 by biomedical researchers Carl Hansen, Véronique Lecault, Kevin Heyries, Daniel Da Costa and Oleh Petriv. In November 2016, the company received a 645K grant from the Bill & Melinda Gates Foundation to develop a test for tuberculosis.[4] In September 2018, a $10M series A round of funding was closed.[5] In May 2020, a $105M series B round of funding was closed.[6] [7]

In January 2017, AbCellera announced that it would be collaborating with Pfizer to discover and develop antibodies against "undisclosed membrane protein targets.”[8] [9]

COVID-19 treatments: initial expansion and subsequent decline

In June 2020, AbCellera announced it had begun the world's first study of a potential antibody treatment against COVID-19, with a Phase 1 trial of LY-CoV555 (Bamlanivimab), in collaboration with Eli Lilly and Company.[10] The drug was granted an Emergency Use Authorization by the U.S. Food and Drug Administration in November 2020, and subsequently renewed in February and March 2021.[11] [12] The EUA was revoked in April 2021, with the FDA citing an updated conclusion that "the known and potential benefits of bamlanivimab alone no longer outweigh the known and potential risks for the product," because of significantly reduced efficacy against emerging variants of SARS-CoV-2.[13]

In September 2021, the company announced a multi-year agreement with Moderna to develop mRNA-based antibody treatments against multiple diseases.[14]

In January 2022, the company received a $1.5 million grant from the Bill & Melinda Gates Foundation to identify monoclonal antibodies against respiratory syncytial virus (RSV).[15] A second COVID-19 monoclonal antibody therapy (Bebtelovimab) was given Emergency Use Authorization in February 2022, with the U.S. Government committing to a $720 million purchase of up to 600,000 doses.[16] However, several months later, the FDA removed the authorization, due to lack of effectiveness.[17]

As of November 2022 following the FDA decision to remove authorization for using Abcellera COVID antibodies, the company has no drugs on the market. As a result of the discontinuation of the COVID antibodies, the stock price subsequently plummeted by over 95% from IPO, with increasing net losses amounting to -$36.9M from Q2 2024.[18] [19]

See also

Notes and References

  1. Niiler. Eric. Darpa Cranks Up Antibody Research to Stall Coronavirus. 2020-02-14. Wired. 2020-02-16. Condé Nast.
  2. News: Cumbers. John. The Synthetic Biology Companies Racing To Fight Coronavirus. 2020-02-05. Forbes. 2020-02-16.
  3. News: Shore. Randy. B.C.'s biotech leaders are growing up and going global. 2017-03-03. Vancouver Sun. 2020-02-16. Postmedia Network.
  4. Web site: November 2016 . Grant: AbCellera Biologics Inc. . live . https://web.archive.org/web/20220504180504/https://www.gatesfoundation.org/about/committed-grants/2016/11/opp1163209 . 2022-05-04 . 2020-02-16 . Bill & Melinda Gates Foundation.
  5. News: McGrane. Clare. AbCellera raises $10M for machine-learning fueled antibody discovery platform. 2018-09-27. GeekWire. 2020-02-16.
  6. News: Gormley. Brian. 2020-05-27. AbCellera Banks $105 Million for Antibodies, Including for Covid-19. en-US. Wall Street Journal. 2020-07-21. 0099-9660.
  7. Web site: Knapp. Alex. AbCellera Raises $105 Million To Boost Drug Discovery Against Coronavirus And Other Diseases. 2020-07-21. Forbes. en.
  8. Web site: Heyries . Kevin . 2017-01-05 . AbCellera Announces Multi-Target Research Collaboration with Pfizer . live . https://archive.today/20220504185031/https://www.abcellera.com/news/2017-01-collaboration-with-pfizer . 2022-05-04 . 2022-05-04 . AbCellera.
  9. Web site: 2021-02-28 . Research programme: transmembrane protein modulators - AbCellera/Pfizer . live . https://web.archive.org/web/20220504190007/https://adisinsight.springer.com/drugs/800048645 . 2022-05-04 . 2022-05-04 . Adis Insight - Springer Science+Business Media.
  10. News: Lilly Begins World's First Study of a Potential COVID-19 Antibody Treatment in Humans. Lilly. 4 June 2020. 1 June 2020.
  11. 2021-03-02 . An EUA for Bamlanivimab—A Monoclonal Antibody for COVID-19 . JAMA . 325 . 9 . 880–881 . 10.1001/jama.2020.24415 . 33306087 . 0098-7484. free .
  12. Web site: Hinton . Denise M. . 2021-04-16 . RE: Emergency Use Authorization 090 . live . https://web.archive.org/web/20220406215515/https://www.fda.gov/media/147629/download . 2022-04-06 . 2022-05-04 . U.S. Food & Drug Administration.
  13. Web site: Office of the Commissioner . 2021-04-19 . Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Monoclonal Antibody Bamlanivimab . live . https://archive.today/20210527190156/https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-monoclonal-antibody-bamlanivimab . 2021-05-27 . 2022-05-04 . . en.
  14. News: Khandekar . Amruta . 2021-09-15 . AbCellera and Moderna team up to develop antibody therapies . en . . 2022-05-04.
  15. Web site: January 2022 . AbCellera Biologics Inc. . live . https://archive.today/20220504180519/https://www.gatesfoundation.org/about/committed-grants/2022/01/inv027467 . 2022-05-04 . 2022-05-04 . . en.
  16. Web site: Tong . Amber . 2022-02-14 . As Omicron rages, FDA clears Eli Lilly/AbCellera's new antibody days after $720M supply deal . live . https://archive.today/20220215130659/https://endpts.com/as-omicron-rages-fda-clears-eli-lilly-abcelleras-new-antibody-days-after-720m-supply-deal/ . 2022-02-15 . 2022-05-04 . Endpoints News . en.
  17. Web site: November 23, 2022 . FDA pulls U.S. authorization for Eli Lilly's COVID drug bebtelovimab . Reuters.
  18. News: August 6, 2024 . AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Misses Revenue Estimates .
  19. Web site: Google Finance . AbCellera Biologics Inc .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "AbCellera".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.